AUTHORS
Shih-Wen Lin, Carolina Reyes, PhD2, Anthony Masaquel, PhD, MPH3, Rongrong Wang4, Shilpa Kamdar5, Shu Wang6, Melody Chang, RPh, MBA, BCOP7
AFFILIATIONS
1 Genentech, Inc., South San Francisco, California, United States
2 Genentech, Inc., South San Francisco, California, United States
3 Genentech, Inc., South San Francisco, California, United States
4 Genentech, Inc., South San Francisco, California, United States
5 Genesis Research Group, Hoboken, New Jersey, United States
6 Genesis Research Group, Hoboken, New Jersey, United States
7 American Oncology Network, Fort Myers, Florida, United States
ABSTRACT
Background: Healthcare providers in the community oncology setting frequently perceive new targeted NHL therapies to be prohibitively expensive for patients. Concerns over financial burden may influence treatment decisions despite evidence of clinical efficacy and safety of treatments. The objective of this study was to evaluate the patient's financial responsibility among individuals insured by commercial and Medicare (Supplemental and Advantage) plans who received selected NHL treatment regimens.
Methods: This retrospective analysis utilized two large administrative claims databases: Merative MarketScan® (commercial and Medicare Supplemental) and IQVIA PharMetrics® Plus Closed Health Plan claims (commercial and Medicare Advantage). Patients were identified using outpatient and pharmacy claims for the following treatment regimens: mosunetuzumab; glofitamab; rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); and polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP). Across both databases, identification windows spanned from January 2022 or the date of treatment-specific Food and Drug Administration approval (if later than January 2022), through September 2025. Patients enrolled in health maintenance organizations or capitated plans were excluded as bundled claims in these plan designs obscure treatment-specific cost assessments. Patient financial responsibility was calculated as the difference between the allowed amount and the actual amount paid by health plans for all regimen-specific drug claims occurring on a single treatment day, which is typically the copay, deductible, and coinsurance in most circumstances. Outcomes included mean patient financial responsibility per treatment claim and the percentage of treatment claims that had a patient financial responsibility of $0. Patient financial responsibility was stratified by insurance type.
Results: In MarketScan, there were 32 patients with 243 mosunetuzumab claims, 42 with 207 glofitamab claims, 2,398 with 9,625 R-CHOP claims, and 381 with 1,572 Pola-R-CHP claims. In PharMetrics Plus, there were 65 patients with 352 mosunetuzumab claims, 18 with 72 glofitamab claims, 5,315 with 20,763 R-CHOP claims, and 519 with 1,891 Pola-R-CHP claims. In MarketScan, 27% of patients had Medicare Supplemental insurance, while the remaining had commercial. In PharMetrics Plus, 16% of patients had Medicare Advantage insurance, 41% had commercial insurance, and the remaining were self-employed or had another insurance type.
The mean patient financial responsibility per treatment claim ranged from $69.90 to $118.30 in MarketScan and $26.80 to $1,023.20 in PharMetrics Plus. The mean patient financial responsibility (range) was generally higher for claims in patients covered by Medicare Advantage ($394.00–$2,478.70) compared with those covered by commercial ($7.60–$926.20 in PharMetrics Plus; $78.20–$139.80 in MarketScan) or Medicare Supplemental ($0–$54.30) plans.
Despite substantial variability in patient financial responsibility in both datasets, most treatment claims had a patient financial responsibility of $0. In MarketScan, 84% of mosunetuzumab claims (204/243), 85% of glofitamab claims (175/207), 86% of R-CHOP claims (8,286/9,625), and 85% of Pola-R-CHP claims (1,336/1,572) had a patient financial responsibility of $0. Similarly, in PharMetrics Plus, 82% of mosunetuzumab claims (287/352), 97% of glofitamab claims (70/72), 78% of R-CHOP claims (16,154/20,763), and 83% of Pola-R-CHP claims (1,567/1,891) had a patient financial responsibility of $0. Across regimens, the percentage of claims (range) with a patient financial responsibility of $0 was lower with Medicare Advantage (47–77%) compared with commercial (83–97% in PharMetrics Plus; 80–88% in MarketScan) and Medicare Supplemental (81–100%) plans.
Conclusions: This analysis demonstrates that, while financial burden for selected NHL treatment regimens is an important concern given the wide range of patient financial responsibility observed, the majority of claims had a patient financial responsibility of $0, albeit some based on small sample sizes. While information on patient financial assistance through copay or foundation programs was not included in this analysis, these results provide valuable transparency regarding financial responsibility among patients with NHL insured by commercial and Medicare (Supplemental and Advantage) plans in the United States.
DISCLOSURES
Shih-Wen Lin: Roche - Current equity holder in publicly-traded company; Roche/Genentech - Current Employment